← Back to AMLX

Amylyx Pharmaceuticals, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Mar 2026Filed 06/08/2026Sep 2025Filed 06/11/2025Jun 2025Filed 06/08/2026Mar 2025Filed 06/08/2026Sep 2024Filed 06/11/2025Jun 2024Filed 06/11/2025Mar 2024Filed 06/11/2025
$0$0$0$0.4−$1$89
−$43−$41−$34−$41−$36−$73−$73−$119
−$0.39−$0.37−$0.37−$0.46−$0.42−$1.07−$1.07−$1.75
111111938986686868

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.